Follow-The-Filings

Security · featured owners

RXRX Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc. COMMON STOCK Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 1.0%
  • $152M
  • 1 add

Who owns this now

Largest portfolio weights among featured holders · max 1.0% (Cathie Wood - Ark Investment Management) · not free-float ownership

  1. Cathie Wood add 0.98%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Cathie Wood - Ark Investment Management 2026 Q2 0.98% Add +2.8% 41,337,632 $152M history

1 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $44.58M $58.84M $74.68M
Gross profit * $1.99M $13.6M $3.73M
Gross margin * 4.5% 23.1% 5.0%
Net income -$328.07M -$463.66M -$644.76M
Net margin * -736.0% -788.0% -863.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $438.14M $714.27M $812.84M
Total non-current assets * $215.56M $734.33M $661.28M
Total assets $0.654B $1.45B $1.47B
Total current liabilities $93.17M $187.47M $147.71M
Total non-current liabilities * $97.09M $226.34M $195.56M
Total equity $0.463B $1.03B $1.13B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$287.78M -$359.17M -$371.81M
Cash from investing -$10.23M $260.06M -$16.87M
Cash from financing $140.13M $304.12M $521.53M
Net change in cash -$157.69M $201.6M $150.9M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders